Your browser is no longer supported. Please, upgrade your browser.
ADAP Adaptimmune Therapeutics plc monthly Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-0.96 Insider Own0.10% Shs Outstand154.67M Perf Week4.03%
Market Cap713.52M Forward P/E- EPS next Y-0.93 Insider Trans-82.05% Shs Float11.25M Perf Month11.59%
Income-122.80M PEG- EPS next Q-0.23 Inst Own84.30% Short Float26.37% Perf Quarter-38.01%
Sales3.20M P/S222.98 EPS this Y-33.20% Inst Trans1.49% Short Ratio2.37 Perf Half Y-57.82%
Book/sh2.43 P/B2.02 EPS next Y-4.50% ROA-33.70% Target Price- Perf Year414.08%
Cash/sh2.75 P/C1.78 EPS next 5Y1.00% ROE-44.90% 52W Range0.85 - 13.40 Perf YTD309.17%
Dividend- P/FCF- EPS past 5Y-46.40% ROI-113.30% 52W High-63.36% Beta2.23
Dividend %- Quick Ratio12.20 Sales past 5Y-30.30% Gross Margin- 52W Low477.65% ATR0.44
Employees400 Current Ratio12.20 Sales Q/Q500.00% Oper. Margin- RSI (14)44.93 Volatility9.33% 8.54%
OptionableYes Debt/Eq0.00 EPS Q/Q38.70% Profit Margin- Rel Volume1.00 Prev Close4.61
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume1.25M Price4.91
Recom2.40 SMA200.37% SMA50-23.43% SMA200-24.26% Volume1,224,704 Change6.51%
Apr-22-20Initiated Mizuho Neutral $3
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Nov-20-20 07:30AM  
Nov-19-20 09:00AM  
Nov-12-20 08:00AM  
Nov-09-20 03:18PM  
Nov-08-20 10:00AM  
Nov-06-20 11:01AM  
Nov-05-20 07:30AM  
06:15AM  
Oct-22-20 08:00AM  
Oct-16-20 12:41PM  
Oct-15-20 04:40PM  
Oct-13-20 12:04PM  
Oct-09-20 06:18AM  
Aug-28-20 10:30AM  
Aug-11-20 12:00PM  
Aug-10-20 07:40AM  
07:25AM  
Aug-06-20 07:30AM  
Jul-23-20 04:00PM  
Jul-22-20 08:00AM  
Jul-05-20 02:25PM  
Jun-23-20 11:26AM  
Jun-17-20 09:33AM  
08:52AM  
Jun-12-20 06:30AM  
Jun-08-20 10:30AM  
Jun-04-20 10:45AM  
Jun-02-20 04:37AM  
12:38AM  
Jun-01-20 09:39PM  
12:51PM  
11:01AM  
09:38AM  
06:09AM  
06:00AM  
04:15AM  
May-29-20 05:08PM  
02:20PM  
10:32AM  
10:24AM  
07:30AM  
May-19-20 07:02AM  
May-14-20 12:00PM  
08:55AM  
07:30AM  
May-12-20 08:00AM  
06:07AM  
Apr-29-20 08:00AM  
Apr-28-20 12:00PM  
08:00AM  
Mar-20-20 10:40PM  
Mar-11-20 11:35AM  
Feb-29-20 08:31AM  
Feb-27-20 07:30AM  
06:00AM  
Feb-24-20 03:15PM  
Feb-20-20 04:00PM  
Feb-18-20 08:00AM  
Feb-07-20 04:05PM  
Feb-05-20 11:30AM  
Feb-03-20 09:13AM  
Jan-24-20 04:30PM  
Jan-22-20 01:18PM  
08:48AM  
08:25AM  
06:48AM  
Jan-21-20 04:08PM  
Jan-17-20 12:00PM  
Jan-15-20 08:22AM  
Jan-14-20 12:29PM  
07:55AM  
02:08AM  
Jan-13-20 08:30AM  
02:00AM  
Dec-30-19 05:25AM  
Dec-16-19 05:45AM  
Dec-03-19 02:20PM  
08:30AM  
Nov-17-19 11:40AM  
Nov-16-19 02:00AM  
Nov-06-19 07:30AM  
Nov-01-19 08:00AM  
Oct-31-19 01:52PM  
06:09AM  
Oct-09-19 08:00AM  
Oct-01-19 08:00AM  
Sep-30-19 08:45AM  
Sep-16-19 06:41AM  
Sep-10-19 09:01AM  
Sep-09-19 08:00AM  
Aug-27-19 02:11PM  
08:00AM  
Aug-16-19 11:23AM  
Aug-01-19 10:24PM  
07:15AM  
07:15AM  
Jul-29-19 04:05PM  
Jul-25-19 08:00AM  
Jul-22-19 08:00AM  
Jul-18-19 11:00AM  
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rawcliffe AdrianChief Executive OfficerSep 01Sale8.512,77623,6373,076Sep 02 09:00 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerAug 03Sale8.74200,0001,748,1800Aug 04 09:02 PM
Lunger JohnChief Patient Supply OfficerAug 03Sale9.254,82344,6138,066Aug 04 09:02 PM
Rawcliffe AdrianChief Executive OfficerAug 03Sale9.252,78825,7893,064Aug 04 09:01 PM
Wood GavinChief Financial OfficerJun 29Buy1.6233,00053,46033,000Jun 30 09:01 PM
Alleva Lawrence MDirectorJun 09Buy1.8912,90024,38112,900Jun 11 09:00 PM
Noble JamesDirectorMay 29Sale9.33500,0004,666,0000Jun 02 09:30 PM
Sonsini Peter W.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:55 PM
SANDELL SCOTT D10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:54 PM
Florence Anthony A. Jr.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
MOTT DAVID MDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:53 PM
BASKETT FOREST10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:51 PM
Behbahani AliDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
Norry ElliotChief Medical OfficerJan 14Sale5.139114,6781,326Jan 15 08:03 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.132,39712,3083,605Jan 15 08:03 PM
Rawcliffe AdrianChief Executive OfficerJan 14Sale5.133,23616,6163,166Jan 15 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 14Sale5.131,1445,8741,681Jan 15 08:02 PM
Noble JamesDirectorJan 13Sale4.67300,0001,400,0000Jan 15 08:01 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerJan 13Sale4.50100,000450,0000Jan 15 08:02 PM
Rawcliffe AdrianChief Executive OfficerJan 06Sale1.205,9007,0805,804Jan 07 08:00 PM
Bertrand William C JRChief Operating OfficerJan 06Sale1.203,7314,4775,632Jan 07 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 06Sale1.201,1481,3781,677Jan 07 08:01 PM